Among the use of a combination chemotherapy and immunotherapy, researchers have investigated the efficacy of using anti-PD-1 and anti-CTLA-4 in different situations related to NSCLC [69]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.